Advertisement

Theoretische Überlegungen zur Kombination therapeutischer Strategien

  • H. Hinterhuber
Chapter

Zusammenfassung

In den letzten zehn Jahren konnten in der psychiatrischen Therapieforschung eine Fülle von neuen Erkenntnissen gewonnen werden, die eine positive Beeinflussung der vielgestaltigen Erlebnis- und Verhaltensweisen schizophrener Menschen ermöglichen. Schwerpunkte der künftigen Forschung werden einerseits Maßnahmen zur Verbesserung der Wirksamkeit und Verträglichkeit psychopharmakologischer Behandlungsstrategien sein, andererseits die Umsetzung der neu gewonnenen Erkenntnisse bezüglich der Umwelteinflüsse, die den Erkrankten und sein soziales Umfeld betreffen. Biologische und psychosoziale, angeborene und erworbene, innerpsychische und zwischenmenschliche Aspekte können und dürfen nur gemeinsam betrachtet werden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Baldessarini RJ, Lipinski JF. Toxicity and side effects of antipsychotic, antimanic and antidepressant medications. Psychiatr Ann 1976; 6: 484–493.Google Scholar
  2. Becker RE. Evaluation of an amitriptyline-perphenazine combination in chronic schizophrenia. Am J Psychiatry 1970; 127: 127–131.Google Scholar
  3. Bleuler M. Die schizophrenen Geistesstörungen im Lichte langjähriger Kranken-und Familiengeschichten. Stuttgart: Thieme, 1972.Google Scholar
  4. Broadbent DE. Decision and Stress. London: Academic, 1971.Google Scholar
  5. Chapman LJ, Chapman JP. Disordered Thought in Schizophrenia. New York: Appleton-CenturyCrofts, 1973.Google Scholar
  6. Chouinard G, Annable L, Serrano M, Albert JM, Charetpe R. Amitriptyline-perphenazine interaction in ambulatory schizophrenic patients. Arch Gen Psychiatry 1975; 32: 1295 1307.Google Scholar
  7. Ciompi L. The natural history of schizophrenia in the long term. Br J Psychiatry 1980; 136: 413–420.PubMedCrossRefGoogle Scholar
  8. Ciompi L. Auf dem Weg zu einem kohärenten multidimensionalen Krankheits-und Therapie-verständnis der Schizophrenie: Konvergierende neue Konzepte. In: Boker W, Brenner HD, Hrsg. Bewältigung der Schizophrenie. Bern-Stuttgart-Toronto: Huber, 1986: 47–61.Google Scholar
  9. El - Yousef MK. Tricyclic antidepressants and phenothiazines. Jama 1974; 229:1419.Google Scholar
  10. Falconer DS. The inheritance of lability to certain diseases estimated from the incidence among relatives. Ann Hum Genet 1965; 29: 51–76.Google Scholar
  11. Freeman H.The therapeutic value of combinations of psychotropic drugs. Psychopharmacol Bull 1967; 4: 1–27.PubMedGoogle Scholar
  12. Goldstein MJ, Rodnick EH, Evans JR, Ram P, Steinberg M. Drug and family therapy in the aftercare of acute schizophrenics. Arch Gen Psychiatry 1978; 35: 1169–1177.PubMedCrossRefGoogle Scholar
  13. Gottesman II, Shields J. A critical review of recent adoption, twin and genetic perspectives. Schizophr Bull 1976; 2: 360–398.PubMedCrossRefGoogle Scholar
  14. Gram LF, Overo KF. Drug interaction: Inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. Br Med J 1972; 1: 463–465.PubMedCentralPubMedCrossRefGoogle Scholar
  15. Gram LF, Reisby N, Ibsen I, Nagy A, Dencker SJ, et al. Plasma levels and antidepressive effects of imipramine Clin Pharmacol Ther 1976; 19: 318–324.Google Scholar
  16. Greenblatt M, Solomon H, Evans AS, Brooks GW. Drugs and Social Therapy in Chronic Schizophrenia. Springfield III.: Ch. Thomas, 1965.Google Scholar
  17. Grinspoon L, Ewalt JR, Shader R. Psychotherapy and pharmacotherapy in chronic schizophrenia. Am J Psychiatry 1968; 124: 1645–1657.PubMedGoogle Scholar
  18. Grohmann R, Strauss A, Gehr C, Ruther E, Hippius H.Zur Praxis der klinischen Therapie mit Psychopharmaka. Pharmakopsychiat 1980; 13: 1–19.CrossRefGoogle Scholar
  19. Haracz JL. A neural plasticity hypothesis of schizophrenia. Neurosci Biobehav Rev 1984; 8: 59–71.CrossRefGoogle Scholar
  20. Hinterhuber H. Zur Katamnese der Schizophrenien: Eine klinisch statistische Untersuchung lebenslanger Verläufe. Fortschr Neurol Psychiatr 1973; 41: 527–558.Google Scholar
  21. Hogarty GE, McEvoy MP, Munetz M, Dibarry AL, Bartone P, et al. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Arch Gen Psychiatry 1988; 45: 797–805.PubMedCrossRefGoogle Scholar
  22. Huber G, Gross G, Schüttler R. Schizophrenie, eine Verlaufs-und sozialpsychiatrische Studie. Berlin-Heidelberg-New York: Springer, 1979.Google Scholar
  23. Kuss HJ, Jungkunz G, Dieterle D. Veränderung der klinischen Wirkung des Amitriptylins durch Kombinationsbehandlung. Arzneimittelforschung 1980; 30 (II): 1200.Google Scholar
  24. Leff J, Vaughn C. The role of maintenance therapy and relatives’ expressed emotion in relapse of schizophrenia: A two-year follow-up. Br J Psychiatry 1981; 139: 102–104.PubMedCrossRefGoogle Scholar
  25. May Pra. Treatment of Schizophrenia: A Comparative Study of Five Treatment Methods. New York: Science House, 1968.Google Scholar
  26. May Pra. When, what and why? Psychopharmacotherapy and other treatments in schizophrenia. Compr Psychiatry 1976; 17: 683–693.Google Scholar
  27. Nüchterlein KH, Snyder KS, Dawson Me, Rappe S, Gitlin M, et al. Expressed emotion, fixed dose fluphenazine decanoate maintenance, and relapse in recent-onset schizophrenia. Psychopharmacol Bull 1986; 22: 633–639.Google Scholar
  28. Rosenthal D. Genetic Theory and Abnormal Behavior. New York: McGraw Hill, 1970.Google Scholar
  29. Ruther E. Interaction of neuroleptic clozapine and haloperidol. ( Submitted to proceedings of CINP Congress, Quebec 1976 ).Google Scholar
  30. Strauss JS, Carpenter WT Jr. Schizophrenia. New York: Plenum, 1981.CrossRefGoogle Scholar
  31. Süllwold L. Schizophrenie. Stuttgart-Berlin-Köln-Mainz: Kohlhammer, 1983.Google Scholar
  32. Talbot DR. Are tranquilizer combinations more effective than a single tranquilizer? Am J Psychiatry 1964; 121: 597–600.PubMedGoogle Scholar
  33. Vaughn CE, Leff JP. The influence of family and social factors on the course of psychiatric illness: A comparison of schizophrenic and depressed neurotic patients. Br J Psychiatry 1976; 129: 125–137.PubMedCrossRefGoogle Scholar
  34. Venables PH. Selectivity of attention, withdrawal and cortical activation. Arch Gen Psychiatry 1963; 9: 92–96.CrossRefGoogle Scholar
  35. Wing JK, Brown GW. Institutionalism and Schizophrenia. London: Cambridge University, 1970. YATES AJ. Data-processing levels and thought disorder in schizophrenia. Aust J Psychol 1966; 18: 103–117.CrossRefGoogle Scholar
  36. Zander KJ, Ruther E. Influence of clozapine on neuroleptic extrapyramidal motor disturbance. Drug Res 1978; 28: 1495–1496.Google Scholar
  37. Zubin J, Spring B. Vulnerability: A new view of schizophrenia. J Abnorm Psychol 1977; 86: 103–123.PubMedCrossRefGoogle Scholar

Copyright information

© Friedr. Vieweg Verlag, Braunschweig/Wiesbaden 1990

Authors and Affiliations

  • H. Hinterhuber

There are no affiliations available

Personalised recommendations